Early prenatal diagnosis of causative homozygous variants in ASCC1 in a fetus with cystic hygroma and additional homozygous variants of unknown significance associated with a neurological phenotype not visible in early gestation: Dual diagnosis or not?


Journal

Prenatal diagnosis
ISSN: 1097-0223
Titre abrégé: Prenat Diagn
Pays: England
ID NLM: 8106540

Informations de publication

Date de publication:
Mar 2024
Historique:
revised: 23 12 2023
received: 27 07 2023
accepted: 26 12 2023
medline: 18 3 2024
pubmed: 12 2 2024
entrez: 11 2 2024
Statut: ppublish

Résumé

A consanguineous couple was referred at 10 weeks of gestation (WG) for prenatal genetic investigations due to isolated cystic hygroma. Prenatal trio exome sequencing identified causative homozygous truncating variants in ASCC1 previously implicated in spinal muscular atrophy with congenital bone fractures. Prenatal manifestations in ASCC1 can usually include hydramnios, fetal hypo-/akinesia, arthrogryposis, contractures and limb deformities, hydrops fetalis and cystic hygroma. An additional truncating variant was identified in CSPP1 associated with Joubert syndrome. Presentations in CSPP1 include cerebellar and brainstem malformations with vermis hypoplasia and molar tooth sign, difficult to visualize in early gestation. A second pregnancy was marked by the recurrence of isolated increased nuchal translucency at 10 + 2 WG. Sanger prenatal diagnosis targeted on ASCC1 and CSPP1 variants showed the presence of the homozygous familial ASCC1 variant. In this case, prenatal exome sequencing analysis is subject to a partial ASCC1 phenotype and an undetectable CSPP1 phenotype at 10 weeks of gestation. As CSPP1 contribution is unclear or speculative to a potentially later in pregnancy or postnatal phenotype, it is mentioned as a variant of uncertain significance. The detection of pathogenic or likely pathogenic variants involved in severe disorders but without phenotype-genotype correlation because the pregnancy is in the early stages or due to prenatally undetectable phenotypes, will encourage the clinical community to define future practices in molecular prenatal reporting.

Identifiants

pubmed: 38342957
doi: 10.1002/pd.6519
doi:

Substances chimiques

ASCC1 protein, human 0
Carrier Proteins 0

Types de publication

Case Reports

Langues

eng

Sous-ensembles de citation

IM

Pagination

352-356

Informations de copyright

© 2024 John Wiley & Sons Ltd.

Références

Tran Mau-Them F, Delanne J, Denommé-Pichon A-S, et al. Prenatal diagnosis by trio exome sequencing in fetuses with ultrasound anomalies: a powerful diagnostic tool. Front Genet. 2023;14(23 mars 2023):1099995. https://doi.org/10.3389/fgene.2023.1099995
Knierim E, Hirata H, Wolf NI, et al. Mutations in subunits of the activating signal cointegrator 1 complex are associated with prenatal spinal muscular atrophy and congenital bone fractures. Am J Hum Genet. 2016;98(3):473-489. https://doi.org/10.1016/j.ajhg.2016.01.006
Oliveira J, Martins M, Pinto Leite R, Sousa M, Santos R. The new neuromuscular disease related with defects in the ASC-1 complex: report of a second case confirms ASCC1 involvement. Clin Genet. 2017;92(4):434-439. https://doi.org/10.1111/cge.12997
Böhm J, Malfatti E, Oates E, et al. Novel ASCC1 mutations causing prenatal-onset muscle weakness with arthrogryposis and congenital bone fractures. J Med Genet. 2019;56(9):617-621. https://doi.org/10.1136/jmedgenet-2018-105390
Guadagnolo D, Mastromoro G, Hashemian NK, et al. Fetal first-trimester cystic hygroma as the prenatal presenting feature of ASCC1-related spinal muscular atrophy with bone fractures 2. J Obstet Gynaecol Can JOGC. 2023;45(8):558-559. https://doi.org/10.1016/j.jogc.2023.05.004
Mace P, Mancini J, Gorincour G, Quarello E. Accuracy of qualitative and quantitative cranial ultrasonographic markers in first-trimester screening for open spina bifida and other posterior brain defects: a systematic review and meta-analysis. BJOG An Int J Obstetrics Gynaecol. 2021;128(2):354-365. https://doi.org/10.1111/1471-0528.16530

Auteurs

Maud Favier (M)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
SoFFoet - Société Française de Foetopathologie, Paris, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Julian Delanne (J)

Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
Centre Pluridisciplinaire de Diagnostic Prénatal, CHU Dijon Bourgogne, Dijon, France.

Guillaume Gorincour (G)

Institut Méditerranéen d'Imagerie Médicale Appliquée à la Gynécologie, la Grossesse et l'Enfance (IMAGE 2), Marseille, France.

Laurence Faivre (L)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Caroline Racine (C)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
Centre Pluridisciplinaire de Diagnostic Prénatal, CHU Dijon Bourgogne, Dijon, France.

Christophe Philippe (C)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
Laboratoire de Génétique, CHR Metz Thionville, Hôpital Mercy, Metz, France.

Yannis Duffourd (Y)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Antonio Vitobello (A)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Thierry Rousseau (T)

Centre Pluridisciplinaire de Diagnostic Prénatal, CHU Dijon Bourgogne, Dijon, France.

Olivia Martz (O)

Centre Pluridisciplinaire de Diagnostic Prénatal, CHU Dijon Bourgogne, Dijon, France.

Georges Tarris (G)

UMR1098, Service de Pathologie, Université Bourgogne-Franche Comté, Dijon, France.

Camélia Oualiken (C)

UMR1098, Service de Pathologie, Université Bourgogne-Franche Comté, Dijon, France.

Christel Thauvin-Robinet (C)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.
Centre Pluridisciplinaire de Diagnostic Prénatal, CHU Dijon Bourgogne, Dijon, France.

Frédéric Tran Mau-Them (FT)

Inserm UMR1231 - GAD, Université Bourgogne Franche-Comté, Dijon, France.
Centre de Référence Maladies Rares Anomalies du développement et Syndromes malformatifs, FHU-TRANSLAD, CHU Dijon Bourgogne, Dijon, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH